Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...

Two family members with a germline ALK-mutant neuroblastoma both experienced complete response to ALK inhibitors in a case study.

If the agency approves its application, the firm will begin a Phase I clinical trial in c-MYC-driven cancers in 2026.

The funds will support a Phase I/II trial of its gene therapy candidate in an aggressive form of dilated cardiomyopathy due to LMNA gene mutations.

The agency approved the treatment based on data from 57 patients with previously treated KRAS-mutant recurrent low-grade serous ovarian cancer.

NEW YORK – Marengo Therapeutics said on Thursday it has started treating patients with certain types of breast cancer in a Phase Ib/II trial of its T-cell agonist, invikafusp alfa, plus Gilead's TROP2 ...

The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.

NEW YORK – Haya Therapeutics on Thursday said it has raised $65 million in a Series A funding round, which it will put toward accelerating development of its therapeutic pipeline, including its long ...

NEW YORK – Isarna Therapeutics said Wednesday that it will discuss with regulators the results of a Phase II trial of its investigational antisense oligonucleotide (ASO), ISTH0036, in patients with ...